Ahmad W. Hajjar

Dr. Ahmad W. Hajjar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
OBOlena Bolgova
Olena Bolgova
AHAhmad W. Hajjar
Ahmad W. Hajjar
VMVolodymyr Mavrych
Volodymyr Mavrych
Neurodegenerative diseases pose major clinical challenges partly due to the underappreciation of the brain’s vascular and clearance systems. Evidence suggests that neurovascular dysfunction and glymphatic impairment are early contributors to disease onset, preceding established markers such as protein aggregation. This review synthesizes recent advances in understanding how disruption of the neurovascular unit (NVU) and glymphatic pathways contributes to neurodegeneration. We analyzed published literature documenting the temporal relationship between vascular dysfunction, glymphatic clearance impairment, and subsequent neurodegenerative pathology, with a focus on identifying therapeutic targets within this axis. Current research demonstrates that blood-brain barrier BBB breakdown, pericyte dysfunction, and compromised cerebral perfusion precede protein aggregation in multiple neurodegenerative disorders. Glymphatic dysfunction, characterized by aquaporin-4 (AQP4) depolarization and abnormalities in meningeal lymphatic vessels, impairs the clearance of neurotoxic metabolites. Novel therapeutic opportunities include the preservation of pericyte function, restoration of AQP4 polarity, enhancement of meningeal lymphatic drainage via vascular endothelial growth factor-C (VEGF-C)/vascular endothelial growth factor receptor-3 VEGFR-3 signaling, and targeted modulation of microRNA and complement pathways that regulate neuroinflammation. By targeting the earliest vascular and glymphatic disruptions, emerging therapeutic strategies may halt or delay disease progression before irreversible neuronal loss occurs. This neurovascular-glymphatic approach represents an unexplored frontier that complements traditional protein-centric therapeutic paradigms, offering new possibilities for early intervention in neurodegenerative disorders.

4 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
LALeen Khaled AlAngari
Leen Khaled AlAngari
LKLeen Khosyfan
Leen Khosyfan
RAReem Alhammad
Reem Alhammad
AHAhmad W. Hajjar
Ahmad W. Hajjar
Efgartigimod is a novel neonatal Fc receptor (FcRn) antagonist that reduces pathogenic immunoglobulin G (IgG) autoantibodies, offering a targeted therapeutic approach for generalized myasthenia gravis (gMG) and other antibody-mediated autoimmune diseases. This narrative review synthesizes clinical trial data, pharmacological insights, and real-world evidence to evaluate efgartigimod’s efficacy, safety, and emerging applications. Phase 3 randomized controlled trials and extension studies demonstrate rapid and sustained improvements in muscle strength and patient-reported outcomes with a favorable safety profile, including reduced reliance on corticosteroids and intravenous immunoglobulin (IVIg). Additionally, observational studies highlight its expanding utility in diverse IgG-mediated disorders such as immune thrombocytopenia (ITP) and autoimmune encephalitis. Efgartigimod thus represents a paradigm shift in autoimmune disease management, enabling precision immunomodulation with the potential for broad clinical impact and improved patient quality of life (QOL).

Verified
Journal Article
Open access
PDF file
VMVolodymyr Mavrych
Volodymyr Mavrych
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
AHAhmad W. Hajjar
Ahmad W. Hajjar
OBOlena Bolgova
Olena Bolgova
Social isolation and loneliness represent critical psychosocial stressors associated with profound hormonal dysregulation and adverse behavioral outcomes. This review synthesizes current evidence on neuroendocrine mechanisms linking perceived and objective social disconnection to health consequences, emphasizing hypothalamic–pituitary–adrenal axis dysfunction, altered glucocorticoid signaling, and inflammatory pathways. Loneliness activates conserved transcriptional responses with upregulated proinflammatory gene expression and downregulated antiviral responses, mediated through sustained cortisol elevation and glucocorticoid resistance. Neural circuit alterations in reward processing, particularly the ventral tegmental area-nucleus accumbens pathway, contribute to anhedonia, social withdrawal, and cognitive decline. Sex differences in neuroendocrine responses reveal distinct hormonal profiles and circuit-specific adaptations. Emerging interventions targeting oxytocin and arginine vasopressin systems, alongside behavioral approaches addressing loneliness-induced cognitive biases, show promise. Critical research gaps include a mechanistic understanding of epigenetic modifications, sex-specific therapeutic responses, and translational applications across diverse populations. Understanding the endocrine–behavior interface in social disconnection offers opportunities for targeted interventions addressing this growing public health challenge.

4 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
OBOlena Bolgova
Olena Bolgova
AHAhmad W. Hajjar
Ahmad W. Hajjar
VMVolodymyr Mavrych
Volodymyr Mavrych
Neurodegenerative diseases pose major clinical challenges partly due to the underappreciation of the brain's vascular and clearance systems. Evidence suggests that neurovascular dysfunction and glymphatic impairment are early contributors to disease onset, preceding established markers such as protein aggregation. This review synthesizes recent advances in understanding how disruption of the neurovascular unit (NVU) and glymphatic pathways contributes to neurodegeneration. We analyzed published literature documenting the temporal relationship between vascular dysfunction, glymphatic clearance impairment, and subsequent neurodegenerative pathology, with a focus on identifying therapeutic targets within this axis. Current research demonstrates that BBB breakdown, pericyte dysfunction, and compromised cerebral perfusion precede protein aggregation in multiple neurodegenerative disorders. Glymphatic dysfunction, characterized by aquaporin-4 (AQP4) depolarization and abnormalities in meningeal lymphatic vessels, impairs the clearance of neurotoxic metabolites. Novel therapeutic opportunities include the preservation of pericyte function, restoration of AQP4 polarity, enhancement of meningeal lymphatic drainage via VEGF-C/VEGFR-3 signaling, and targeted modulation of microRNA and complement pathways that regulate neuroinflammation. By targeting the earliest vascular and glymphatic disruptions, emerging therapeutic strategies may halt or delay disease progression before irreversible neuronal loss occurs. This neurovascular-glymphatic approach represents an unexplored frontier that complements traditional protein-centric therapeutic paradigms, offering new possibilities for early intervention in neurodegenerative disorders.

16 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
AHAhmad W. Hajjar
Ahmad W. Hajjar
MSMuhammad Raihan Sajid
Muhammad Raihan Sajid
This review describes the dramatic transformation that has occurred in the last ten years in the therapeutic landscape for hematologic malignancies, such as leukemias, lymphomas, myelomas, and myelodysplastic syndromes. Treatment paradigms have quickly changed from depending solely on cytotoxic chemotherapy to embracing precision medicine, driven by a previously unprecedented understanding of disease biology and precise molecular changes. The development of powerful immunotherapies (such as CAR T-cell therapy and bispecific antibodies) and innovative targeted agents (like BTK inhibitors, BCL-2 inhibitors, and immunomodulatory medications) is at the heart of this revolution. In addition to evaluating new and synergistic combination strategies, this paper examines the clinical utility, efficacy, and recent developments of these novel agents. It also addresses important issues like managing acquired drug resistance, minimizing financial burden, and adapting clinical trial designs to keep pace with innovation. These advancements are collectively redefining clinical practice, leading to deeper and more durable responses, and significantly improving the prognosis and quality of life for patients.

4 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ghaith K. MansourGhaith K. Mansour
Ghaith K. Mansour
AAAli Faris Altebainawi
Ali Faris Altebainawi
AHAhmad W. Hajjar
Ahmad W. Hajjar
SSSabry Babiker H. Sayed
Sabry Babiker H. Sayed
FAFares A. Alazem
Fares A. Alazem
MSMuhammad Raihan Sajid
Muhammad Raihan Sajid
Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary cardiovascular disorder characterized by unexplained left ventricular hypertrophy, sarcomeric hypercontractility, and dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Current therapies predominantly offer symptomatic relief through indirect modulation of cardiac function, leaving the underlying molecular pathophysiology unaddressed. Mavacamten, a first-in-class, selective allosteric inhibitor of β-cardiac myosin ATPase, exemplifies a precision pharmacological approach by directly targeting the sarcomeric hypercontractility fundamental to obstructive HCM (oHCM). This review synthesizes extensive clinical and preclinical evidence delineating mavacamten’s mechanism of action, pharmacokinetics influenced by CYP2C19 genotype variability, and its demonstrated efficacy and long-term safety in improving functional capacity, symptom burden, and cardiac remodeling. Landmark trials, including EXPLORER-HCM and MAVERICK-HCM, underscore mavacamten’s ability to reduce LVOT gradients, enhance diastolic function, and lower cardiac biomarkers, heralding a paradigm shift from symptomatic management to disease-modifying therapy. Despite current knowledge gaps in long-term outcomes and diverse population responses, mavacamten establishes a critical foundation for molecularly targeted therapeutics in HCM and broader cardiomyopathies.